1-Hexyl n-cyanoacrylate compound (Neucrylate™ AN), a new berry aneurysm treatment. II. Rabbit implant studies: technique and histology
- 1UCSD Medical Center, San Diego, California, USA
- 2Surgery, UCSD Medical Center, San Diego, California, USA
- 3Department of Pathology, UCSD Medical Center, San Diego, California, USA
- 4Holy Cross Hospital, Interventional Neuroradiology, Fort Lauderdale, Florida USA
- 5HSC T12, Stony Brook University Medical Center Stony Brook, New York, USA
- Correspondence to Dr C W Kerber, UCSD Medical Center, 200 W Arbor Dr, San Diego, CA 92103-8756 USA;
- Received 9 November 2010
- Revised 23 March 2011
- Accepted 19 April 2011
- Published Online First 8 June 2011
Introduction Following satisfactory benchtop testing of a new liquid embolic agent, animal implant studies were performed.
Materials and method Elastase aneurysms were created in the right common carotid artery of New Zealand rabbits under approved institutional guidelines. Using direct fluoroscopic control and commercially available microcatheters, the device was introduced into the aneurysms. At 2 months, 12 months and 24 months, follow-up angiography was performed and analyzed. The animals were sacrificed, the brachiocephalic arteries were explanted and fixed, and the histologic appearance of the treated aneurysms was evaluated.
Results The Neucrylate polymerized into an open pore elastic sponge. The open pores permitted fibrous tissue ingrowth. By 2 months, all of the aneurysm necks had been covered by fibrous tissue and a neointima. Two of the aneurysms originally inadequately filled allowed opportunity for retreatment. The reactive change within the aneurysms demonstrated fibroblastic proliferation, collagen and some giant cells but no vascular necrosis. Results at 2 months, 12 months and 24 months were for all practical purposes similar.
Conclusion The lack of necrosis, the mild inflammatory response and the permanence of the implant are interesting in a cyanoacrylate based embolic agent, especially in light of the experience with lower chain homologs and other liquid embolic agents.
Competing interests Charles Kerber MD is a shareholder and chief medical officer in Valor Medical Inc. Ramin Sean Pakbaz is a shareholder in Valor Medical Inc. There are no other competing interests.
Ethics approval This study was conducted with the approval of the Institutional Animal Care and Use Committee.
Provenance and peer review Not commissioned; externally peer reviewed.